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Context: The genetic contribution to liability for opi-
oid dependence is well established; identification of the
responsible genes has proved challenging.
Objective: To examine association of 1430 candidate
gene single-nucleotide polymorphisms (SNPs)withheroin
dependence, reporting here only the 71 SNPs in the chro-
mosome11 gene cluster (NCAM1,TTC12,ANKK1,DRD2)
that include the strongest observed associations.
Design: Case-control genetic association study that in-
cluded 2 control groups (lacking an established optimal
control group).
Setting: Semistructured psychiatric interviews.
Participants: A total of 1459 Australian cases ascer-
tained fromopioid replacement therapy clinics, 531neigh-
borhood controls ascertained from economically disad-
vantaged areas near opioid replacement therapy clinics,
and 1495 unrelated Australian Twin Registry controls not
dependent on alcohol or illicit drugs selected from a twin
and family sample.
Main Outcome Measure: Lifetime heroin depen-
dence.
Results:Comparison of cases with Australian Twin Reg-
istry controls found minimal evidence of association for
all chromosome 11 cluster SNPs (P .01); a similar com-
parisonwith neighborhood controls revealed greater dif-
ferences (P1.8104). Comparing cases (n=1459)with
the subgroup of neighborhood controls not dependent
on illicit drugs (n=340), 3 SNPs were significantly as-
sociated (correcting for multiple testing): ANKK1 SNP
rs877138 (most strongly associated; odds ratio=1.59; 95%
CI, 1.32-1.92;P=9.7107),ANKK1 SNP rs4938013, and
TTC12 SNP rs7130431. A similar pattern of association
was observed when comparing illicit drug–dependent
(n=191) and nondependent (n=340) neighborhood con-
trols, suggesting that liability likely extends to non-
opioid illicit drug dependence. Aggregate heroin depen-
dence risk associated with 2 SNPs, rs877138 and
rs4492854 (located inNCAM1), variedmore than 4-fold
(P=2.7109 for the risk-associated linear trend).
Conclusions:Our results provide further evidence of as-
sociation for chromosome 11 gene cluster SNPswith sub-
stance dependence, including extension of liability to il-
licit drug dependence.Our findings highlight the necessity
of considering drug exposure historywhen selecting con-
trol groups for genetic investigations of illicit drug de-
pendence.
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F AMILYANDTWINSTUDIESHAVEestablished that genetic fac-tors are responsible for a sub-stantial component of liabil-ity for opioid dependence.1,2
However, identification of the genes asso-
ciated with risk has proven challenging.3
Opioid dependence is a complex trait for
which many genes each likely account for
a modest portion of liability. Thus far, no
consistently replicated findings have
emerged fromgenetic association studies fo-
cusing on opioid dependence. Most ge-
netic association studies have had inad-
equate sample size4-10 to detect modest
effects, which, combined with publication
bias for positive findings, increases the like-
lihood of type I error. Underpowered at-
tempts at replication are also predisposed
to type II error. Finally, inconsistency in
findings across studiesmay result fromdif-
ferences in important aspects of experimen-
tal design.11,12 This article examines a cen-
tral component of study design, control
group selection, in the context of a genetic
association study of heroin dependence.
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A number of issues are germane to determining the
most appropriate control group for a genetic associa-
tion study of heroin dependence. Genetic and environ-
mental factors contribute to liability for heroin use13,14
and, among users, for continued use and dependence.14
Investigations in population-based twin samples have at-
tempted to estimate the degree to which these influ-
ences are shared across the stages of this process formore
commonly used substances.15,16 However, owing to the
low prevalence of opioid use, abuse, and dependence,
these samples lack adequate power to conduct similar ex-
aminations.17 Genes whose influence on dependence is
not shared with risk for substance use would not be ex-
pected to display effects in the absence of substance ex-
posure. Ascertainment of exposed, nondependent indi-
viduals is complicated by the relatively low prevalence
of heroin use,18-21 the lack of an identified population en-
riched with users who have survived the period of risk
for developing dependence, the stigma associated with
the drug,18,19 and high rates of progression from use to
dependence due to heroin’s extreme addictivity. Heroin-
dependent individuals are nearly always dependent on
other drugs22,23; however, twin studies have produced
widely varying estimates of the degree to which genetic
and environmental risks for opioid dependence are shared
with other substances.1,2,14,24 Thus, it remains unclear
whether those with a history of having used but not be-
come dependent on other illicit drugs are an adequate
proxy for heroin-exposed controls. Similarly, the poten-
tial for shared genetic risk with more common pheno-
types may supersede the otherwise reasonable argu-
ment25 that the use of an unassessed comparison group
in genetic association studies of low-prevalence dis-
eases results in only a mild reduction in power. These
issues have left investigators conducting genetic asso-
ciation studies of heroin dependence without an obvi-
ous best choice for themost appropriate controls. In fact,
they suggest that various alternative choices may be bet-
ter suited depending on whether a gene’s effects are spe-
cific to heroin dependence or shared with dependence
on other drugs.
This article examines the association of single-
nucleotide polymorphisms (SNPs) with heroin depen-
dence in theComorbidity andTrauma Study.26,27We com-
pare a large Australian sample of heroin-dependent cases
(n=1459) receiving opioid replacement therapy (ORT)
in New South Wales, Australia, with 2 control groups:
(1) controls (n=531) ascertained from economically dis-
advantagedneighborhoods in close proximity toORTclin-
ics who had little or no recreational opioid use lifetime
(includes individuals dependent on alcohol and non-
opioid illicit drugs and nondependent individuals with
high rates of substance exposure); and (2) controls not
meetingDSM-IV criteria for lifetime alcohol or illicit drug
dependence (n=1495unrelated individuals) selected from
a sample of twins and family members (nondependent
with lower rates of drug exposure). The first stage of analy-
ses27 considered only 136 SNPs in opioid receptor genes.
The second stage includes the remaining 1294 SNPs (1430
of 1536 total SNPs were retained for analyses after data
cleaning). We report herein the most significant find-
ings of these analyses involving association with SNPs
in the chromosome 11 cluster of genes (neural cell ad-
hesion molecule 1 [NCAM1; GenBank NM_000615.6],
tetratricopeptide repeat domain 12 [TTC12; GenBank
NM_017868.3], ankyrin repeat and kinase domain con-
taining 1 [ANKK1; GenBank NM_178510.1], and dopa-
mine receptor D2 [DRD2; GenBank NM_000795.3]) for
which awealth of prior studies focusing on licit substance-
related outcomes have reported similar associations. Our
findings exemplify the importance of considering his-
tory of drug exposure in addition to drug dependence
when selecting an appropriate control group.
METHODS
The Comorbidity and Trauma Study, a collaboration of inves-
tigators atWashingtonUniversity School ofMedicine, Queens-
land Institute of Medical Research, and National Drug and Al-
cohol Research Centre of the University of New South Wales,
is a case-control genetic association study of heroin depen-
dence. Details of data collection have been previously re-
ported.26,27 We again27 include data here from pilot study par-
ticipants (25 cases and 25 neighborhood controls) for whom
protocols were identical and assessment comparable.
PARTICIPANTS
Cases recruited from ORT clinics in the greater Sydney, Aus-
tralia, region were required to be aged 18 years or older, to un-
derstand English, and to have participated in ORT for opioid
dependence. Participants reporting recent suicidal intent or cur-
rent psychosis were excluded. Individuals recruited from geo-
graphic areas in proximity to ORT clinics, termed neighbor-
hood controls, were excluded for recreational opioid use more
than 5 times lifetime (data were included from 23 controls who
denied opioid use 5 times at screening but reported greater
use with no dependence symptoms at interview); other inclu-
sion and exclusion criteria were identical to those for cases. In-
stitutional review board approval was obtained from the Uni-
versity of New SouthWales, Washington University School of
Medicine, Queensland Institute of Medical Research, and area
health service ethics committees governing participating clin-
ics. Participants provided written informed consent and were
reimbursed AU$50.00 for out-of-pocket expenses.
Concerns that comparisonswithneighborhoodcontrolsmight
have inadequate power to detect effects on dependence that are
shared with both drug exposure and dependence on other sub-
stances (eg, 191 [36.0%] of the 531 neighborhood controls were
dependent on anonopioid illicit drug; SupplementalTable 1, http:
//digitalcommons.wustl.edu/psychiatry) prompted a decision to
genotype a second,more broadly unaffected control group of un-
related individuals selected from the large Australian Twin Reg-
istry (ATR), including twins and familymembers.28 Inclusion cri-
teriawere institutional reviewboard approval allowinggenotyping
of available DNA. Exclusion criteria were lifetime illicit drug or
alcohol dependence at the prior interview. Non–nicotine-
dependent individuals were preferentially selected; the preva-
lence of nicotine dependence (12.5%) in ATR controls is below
that of the Australian population.
ASSESSMENT
Semistructured psychiatric diagnostic interviews were com-
pleted in person by cases and neighborhood controls; ATR con-
trols had completed telephone interviews previously. Diagnos-
tic sections on illicit drug and alcohol dependenceweremodified
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from the Semistructured Assessment for the Genetics of Alco-
holism–Australia29; the nicotine dependence sectionwasmodi-
fied from the Nicotine Addiction Genetics Study assessment.30
The assessments provided DSM-IV lifetime diagnoses of opi-
oid, cannabis, sedative, stimulant, cocaine, and alcohol abuse
and dependence as well as nicotine dependence. Similar diag-
noses were obtained for Comorbidity and Trauma Study pilot
project participants via the World Health Organization Com-
posite International Diagnostic Interview.31
MARKER SELECTION
The pairwise option of Tagger32 (implemented in Haplo-
view33) with a threshold of r20.8 for most genes and r20.9
for high-priority candidates (eg, opioid receptor genes)was used
to select a custom set of 1536 SNPs. The set provided coverage
of 72 candidate genes, 47 additional SNPs from prior reports,
and 30 ancestry-informative markers.
GENOTYPING
Genotyping was performed on an Illumina BeadStation using
GoldenGate technology.34 Samples ofDNA fromCEPH trio 1334
obtained from theCoriell Cell Repository served as internal qual-
ity controls for clustering and reproducibility. Primary geno-
typic data analyses with Illumina BeadStudio software were fol-
lowed by visual inspection and assessment of data quality and
clustering.
STATISTICAL ANALYSIS
Data Cleaning
Details of data cleaning have been reported previously.27 In brief,
SNPs were excluded owing to genotyping failure (23 SNPs), call
rate less than 95% (9 SNPs), minor allele frequency less than 2%
(47SNPs), andHardy-Weinbergequilibriumdeviations (27SNPs);
1430SNPswere retained for analyses (SupplementalTable2 shows
the complete list). The mean call rate for 1294 nonopioid recep-
tor SNPs remaining after data cleaning exceeded 99.9%. Samples
of DNA from 1506 cases, 538 neighborhood controls, and 1500
ATR controls were genotyped. Data from samples were ex-
cluded owing to genotyping failure (1ATR control), phenotypic-
genotypic sex mismatch (1 case, 2 neighborhood controls), du-
plication due to participation in the project multiple times (29
cases, 3 neighborhood controls—phenotypic data from themost
recent, nonpilot study interview were retained), and cryptic re-
latedness with identity by descent greater than 0.5 (17 cases, 4
neighborhood controls, and 4 ATR controls—individuals with
the higher project identifierwere excluded). The sample used for
analyses consisted of 1459 cases, 531neighborhood controls, and
1495 ATR controls.
Admixture
Cases, neighborhood controls, andATRcontrols all consistedpri-
marily of individuals of European ancestry. The former 2 groups
also included some individuals of Asian ancestry. Principal com-
ponents (PC) analyses (PCAs) were conducted using the smart-
pca program in theEigensoft version 3.0 statistical software pack-
age35 to determine the appropriate admixture correction for each
analysis. The kill r2 setting of 0.8 was used to remove some SNPs
in high linkage disequilibrium (LD)with others in the panelwith
data from 1123 of the 1430 SNPs retained for PCA. Because an-
cestry-informative markers were included in the PCA, Tracy-
Widom statistics could not be used to determine the number of
PCs. SeparatePCA indicated that comparisonsof caseswithneigh-
borhoodcontrols requiredno inclusionof PCs as covariates,while
that comparing cases with ATR controls found at least a trend-
level significance for 4 PCs (for details and PC plots, see the ar-
ticle by Nelson et al27). For analyses that divided the neighbor-
hood controls on the basis of lifetime licit and illicit drug
dependence, a separate PCA run for each comparison found in
each instance a single significant PCwith the following P values:
cases vs neighborhood controls not dependent on nicotine, al-
cohol, and illicit drugs, P=.06; cases vs neighborhood controls
not dependent on alcohol and illicit drugs, P=.06; cases vs neigh-
borhood controls not dependent on illicit drugs, P=.02; cases vs
illicit drug–dependent neighborhood controls, P=.02; and illicit
drug–dependentvsnondependentneighborhoodcontrols,P=.001.
Each of these analyses included a single PC as a covariate to con-
trol for admixture.
Association
Logistic regression analyses performed in PLINK software,36
which included smartpca-derived PCs inmodels to control for
admixture, examined the association between the log-additive
effects of minor allele dosage and case status. We separately
compared 1459 heroin-dependent cases (888 male, 571 fe-
male; mean [SD] age, 36.5 [8.6] years) with 531 neighbor-
hood controls (235male, 296 female;mean [SD] age, 34.7 [10.5]
years) and 1495ATR controls (972male, 523 female;mean [SD]
age, 45.0 [9.5] years). Because of uncertainty regarding themost
appropriate control group for the current investigation and given
within-group differences in the neighborhood controls ob-
served in stage 1 analyses,27 we compared heroin-dependent
cases with subgroups of neighborhood controls who were not
dependent on the following: (1) any illicit drugs (n=340); (2)
any illicit drugs or alcohol (n=275); and (3) any illicit drugs,
alcohol, or nicotine (n=207). We also conducted a within-
group comparison of neighborhood controlswhowere andwere
not illicit drug dependent. A conservative Bonferroni correc-
tion for multiple testing yielded a revised significance thresh-
old of P=3.9106 (ie, .05/1430 SNPs/9 phenotypic compari-
sons: [1] cases vs neighborhood controls; [2] cases vs ATR
controls; cases vs neighborhood controls not dependent on [3]
illicit drugs, [4] illicit drugs or alcohol, and [5] illicit drugs,
alcohol, or nicotine; cases vs neighborhood controls depen-
dent on [6] illicit drugs, [7] illicit drugs or alcohol, and [8] il-
licit drugs, alcohol, or nicotine; and [9] neighborhood con-
trols dependent on illicit drugs vs neighborhood controls not
dependent on illicit drugs). We controlled for the allelic dos-
age of the most strongly associated SNP to examine whether a
single signal adequately explained all observed chromosome
11 gene cluster associations. Consistent with prior reports that
focused on haplotypes spanning these genes, we conducted
analyses using SAS version 9.2 statistical software (SAS Insti-
tute, Inc) to characterize risk (ie, additive, dominant, or reces-
sive) associated with each of the 2 SNPs for whom indepen-
dent signals were found. To estimate their effects in tandem,
we coded a risk level variable that was a sum of their effects. In
doing so, we verified that risk associated with the alternative
routes of obtaining the same risk level (eg, 1 copy of the rs877138
minor allele and the rs4492854 major allele vs 2 copies of the
former and none of the latter) did not differ significantly.
RESULTS
The comparison of cases with ATR controls found P val-
ues greater than .01 for all SNPs in the chromosome 11
gene cluster (select SNPs [ie, primarily thosemore strongly
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associated but also including rs1800497, the Taq1A poly-
morphism] are shown in Table 1). The similar com-
parison of cases with neighborhood controls revealed
greater intergroup differences; however, the minimum
P value (1.8104 for rs7130431)was not significantwith
adjustment for multiple testing (comparisons for addi-
tional genotyped SNPs are shown in Supplemental Table
3; unadjusted [for ethnicity]minor allelic frequencies for
select and additional SNPs are shown in Supplemental
Table 4 and Supplemental Table 5, respectively).
We next examined the effects of dividing neighbor-
hood controls into subgroups based on their lifetime his-
tory of illicit and licit drug dependence (Table 1 shows
a hierarchical breakdown). We found that the associa-
tion signal became stronger as the criterion for exclu-
sion of individuals with lifetime drug dependence was
more narrowly defined (Supplemental Table 6). In the
comparison between heroin-dependent cases and neigh-
borhood controls not dependent on any illicit drugs
(Table 2), significant association was found for 3 SNPs
(rs877138, rs4938013, and rs7130431) in high LD
(Figure)with rs877138, themost strongly associated SNP
(odds rat io [OR] = 1.59; 95% CI, 1.32-1.92;
P = 9.7  107). In contrast, for the comparison be-
tween cases and illicit drug–dependent neighborhood con-
trols, only a single SNP reached even nominal signifi-
cance. Awithin-neighborhood control group comparison
of individuals with and without a lifetime history of il-
licit drug dependence found that rs877138was again the
most highly associated SNP (P = 8.0  104), indicat-
ing that liability attributable to this variant likely ex-
tends to risk for dependence on other illicit drugs.
To determine whether between-group differences in
drug exposure may have contributed to the lack of as-
sociation found with ATR controls, we compared ATR
controls with neighborhood controls not dependent on
illicit drugs. We found significantly greater lifetime use
for all examined illicit drug categories in nondependent
neighborhood controls; differences were most pro-
nounced for cocaine and stimulants (Table 3). Extend-
ing the comparison of nondependent neighborhood con-
trols vs ATR controls to use more than 11 times lifetime
(not shown in Table 3), a similar pattern of between-
group differences was observed: stimulants, 18.2% vs
1.4%, respectively (OR = 15.64; 95%CI, 9.38-26.08); any
noncannabis illicit drug, 19.7% vs 3.0%, respectively
(OR = 7.90; 95% CI, 5.30-11.78); and any illicit drug,
45.3% vs 15.7%, respectively (OR = 4.46; 95% CI, 3.45-
5.76). In an assessment not used for ATR controls, 35.5%
of nondependent neighborhood controls reported hav-
ing seen someone use heroin and 28.4% reported hav-
ing been offered heroin. These results provide strong evi-
dence that the neighborhood controls not dependent on
illicit drugs had substantially greater levels of lifetime drug
use than theATR controls. In addition, a surprisingly large
proportion of these individuals had ready access to heroin.
Inclusion of rs877138 as a covariate in the compari-
son of heroin-dependent cases with neighborhood con-
trols not dependent on illicit drugs yielded suggestive evi-
dence (P  2.5  103) of a second signal involving
Table 1. Comparison of Select Single-Nucleotide Polymorphisms in 1459 Cases vs 1495 Australian Twin Registry Controls
and 531 Neighborhood Controls Using Additive Models
Gene SNP
SNP
Locationa
Minor
Allele
P Value
Heroin-Dependent
Cases vs
ATR Controlsb
Heroin-Dependent
Cases vs
Neighborhood Controls
NCAM1 rs4492854 112488744 G .18 .007
rs11214546 112611738 A .05 .31
rs587761 112615990 A .55 .005
rs2186798 112633271 C .04 .06
TTC12 rs2303380 112705919 G .19 .005
rs10891536 112714638 G .03 .01
rs4938009 112736138 A .03 .005
rs719804 112739985 G .08 .14
rs7130431 112743433 A .12 .001
rs12804573 112746936 G .04 .001
ANKK1 rs877137 112761540 A .12 .001
rs877138 112761718 G .04 .001
rs12360992 112768110 C .25 .001
rs4938013 112769680 A .07 .001
rs2734849 112775370 G .30 .002
rs2734848 112775584 G .02 .008
rs1800497 112776038 T .93 .12
DRD2 rs2234689 112783693 G .03 .007
rs1554929 112783974 A .34 .001
rs2440390 112792088 A .17 .009
rs1076563 112801119 A .11 .003
rs7125415 112815891 A .01 .22
Abbreviations: ATR, Australian Twin Registry; SNP, single-nucleotide polymorphism.
aFrom NCBI build 37.2 (National Center for Biotechnology Information).
bFour principal components were included in the model for admixture correction.
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rs4492854, an NCAM1 SNP. Further analyses sup-
ported a dominantmodel for liability associatedwith this
SNP’s major allele (OR = 1.65; 95% CI, 1.26-2.17). An
examination of aggregate risk associatedwith these 2 SNPs
(ie, the number of rs877138minor alleles [additive] plus
the presence of a copy of the rs4492854 major allele) in
data from cases and nondependent neighborhood con-
trols found that risk varied more than 4-fold on the ba-
sis of these 2 SNPs (Table 4). The proportion of heroin-
dependent individuals (shown as the columnpercentage)
was observed to increase with this measure of aggregate
risk; the P value for the risk-associated linear trend is
2.7  109.
COMMENT
Our data provide strong evidence thatANKK1 andTTC12
SNPs are associatedwith dependence on heroin and other
illicit drugs. These results are an important extension of
previously reported associations that largely involvednico-
tine- or alcohol-related outcomes.37-47 Our findings em-
phasize the necessity of considering both drug exposure
anddependence historywhen selecting a control group for
genetic association studies focusing on drug dependence.
Depending on the control group to which we com-
pared heroin-dependent cases, the magnitude of ob-
served associations varied markedly. The comparison of
cases with ATR controls found scant evidence of asso-
ciation. Although P values exceeded .01 for all SNPs,
rs877138 (P = .04) was among those nominally associ-
ated. Greater evidence of association was observed in the
comparison of cases with neighborhood controls; how-
ever, no P value for any SNPwas within an order of mag-
nitude of the significance level required to correct formul-
tiple testing. Our analyses that divided neighborhood
controls into subgroups based on lifetime history of licit
and illicit drug dependence found that the association
signal became stronger as the exclusionwas definedmore
narrowly to exclude only individuals with lifetime his-
tory of illicit drug dependence.
Three consistent findings emerged with this divi-
sion. First, the comparison of heroin-dependent caseswith
nondependent neighborhood controls found 3 SNPswith
P values significant after correction for multiple testing.
Second, the comparison of cases with illicit drug–
dependent neighborhood controls was remarkable for the
complete lack of even nominally significant differences
for TTC12 and ANKK1 SNPs. Third, the comparison of
nondependent and illicit drug–dependent neighbor-
hood controls found a pattern of association nearly iden-
tical to the comparison of the former with cases, with the
smaller size of the latter sample limiting overall power.
A post hoc comparison of nondependent neighborhood
controlswith a combined groupof heroin-dependent cases
and illicit drug–dependent controls found that signifi-
cance improved incrementally for the association with
Table 2. Comparison of Single-Nucleotide Polymorphisms Between Groups Using Additive Models
Gene SNP
P Valuea
Heroin-Dependent
Cases (n = 1459) vs
Neighborhood Controls
Not Dependent
on Illicit Drugs
(n = 340)
Heroin-Dependent
Cases (n = 1459) vs
Illicit Drug–Dependent
Neighborhood Controls
(n = 191)
Within-Neighborhood
Control Comparison
of Those Not Dependent
on Illicit Drugs (n = 340)
vs Those Dependent
(n = 191)
LD of
SNP With
rs877138, r 2
NCAM1 rs4492854 .002 .59 .13 0.00
rs11214546 .33 .002 .003 0.00
rs587761 .01 .15 .59 0.02
rs2186798 .19 .16 .81 0.00
TTC12 rs2303380 .000035 .56 .003 0.70
rs10891536 .0005 .88 .03 0.37
rs4938009 .0005 .89 .02 0.35
rs719804 .02 .47 .02 0.26
rs7130431 .0000028b .78 .005 0.91
rs12804573 .00007 .53 .04 0.48
ANKK1 rs877137 .000024 .56 .02 0.51
rs877138 .00000097b .83 .001 1.00
rs12360992 .000095 .45 .05 0.44
rs4938013 .0000013b .88 .001 0.89
rs2734849 .00016 .48 .06 0.38
rs2734848 .001 .93 .02 0.38
rs1800497 .047 .92 .22 0.15
DRD2 rs2234689 .001 .93 .02 0.38
rs1554929 .000066 .39 .06 0.45
rs2440390 .00042 .83 .008 0.25
rs1076563 .0002 .57 .05 0.27
rs7125415 .12 .77 .32 0.05
Abbreviations: LD, linkage disequilibrium; SNP, single-nucleotide polymorphism.
aOne principal component was included in each model for admixture correction.
bSignificant with correction for multiple testing.
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rs877138 (P = 6.4 107).Our results provide strong evi-
dence that a block of ANKK1 and TTC12 SNPs in high
LD is associated with heroin and other illicit drug de-
pendence. The large difference in the strength of asso-
ciation observed in the comparison with nondependent
neighborhood controls (individuals with high exposure
to illicit drugs, either via use or from residing in envi-
ronments withwidespread drug availability) vs ATR con-
trols (individuals not dependent on alcohol or illicit drugs,
with significantly lower illicit drug exposure) strongly
suggests that this liability likely represents risk of de-
pendence contingent on drug exposure.Our findings raise
an intriguing possibility that nondependent highly sub-
stance-exposed controls might be particularly informa-
tive for attempts to identify polymorphisms associated
with drug dependence liability.
The 3 SNPs (rs877138, rs4938013, and rs7130431)
for which we observed significant association are lo-
cated in a region spanning ANKK1 and TTC12. High LD
between SNPs in these genes prevents determination,
without additional sequencing, of the gene primarily con-
tributing to liability. For example, rs877138 is located
in the 5' flanking region 2005 base pairs upstream from
the first exon of ANKK1 but is in complete LD with sev-
eral intronic TTC12 SNPs. Both rs4938013, an exonic
ANKK1 SNP resulting in a synonymous substitution, and
rs7130431, an intronic TTC12 SNP, are in high LD with
rs877138 (respective r2 values of 0.89 and 0.91), consis-
tent with a single association signal. Although nomi-
nally significant association extends to the Taq1A poly-
morphism (rs1800497) and DRD2 SNPs, analyses that
controlled for allelic dose of rs877138 found no evi-
dence of an independent signal involving this func-
tional polymorphism or any other ANKK1, TTC12, or
DRD2 SNP. Since prior studies6,11,48-52 that reported an as-
sociation of rs1800497 with opioid dependence geno-
typed few or no additional ANKK1 SNPs, the signal they
observed may have resulted from similar LD. The only
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Figure. Linkage disequilibrium analysis of select TTC12, ANKK1, and DRD2 single-nucleotide polymorphisms (r 2 values are shown).
Table 3. Comparison of 1495 Australian Twin Registry
Controls With 340 Neighborhood Controls
Not Dependent on Illicit Drugs
Illicit Drug
Prevalence of Use
by Control Group, %
OR (95% CI)ATR
Nondependent
Neighborhood
Cannabis 44.4 71.1 4.22 (3.21-5.54)
Stimulant 6.8 44.4 10.91 (8.14-14.63)
Opioid 7.4 10.6 1.49 (1.00-2.22)
Sedative 3.5 12.9 4.12 (2.71-6.28)
Cocaine 2.3 25.9 14.57 (9.63-22.03)
Any 49.8 79.1 3.81 (2.88-5.05)
Any noncannabis 15.0 50.6 5.78 (4.48-7.46)
Abbreviations: ATR, Australian Twin Registry; OR, odds ratio.
JAMA PSYCHIATRY/VOL 70 (NO. 3), MAR 2013 WWW.JAMAPSYCH.COM
330
©2013 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 08/11/2015
association not attributable to LD in our sample in-
volved rs4492854, an NCAM1 SNP, for which risk was
best explained by a dominant model. Owing to the com-
plete lack of LD between rs877138 and rs4492854, we
instead examined risk associated with these SNPs in tan-
demrather than thehaplotype-based analyses used inprior
investigations37,39,41,43 and found greater than 4-fold varia-
tion in risk (OR = 4.30; 95% CI, 2.36-7.84) across com-
binations of these 2 SNPs.
Our results are broadly consistent with a literature37-46
inwhich, led by the efforts of Gelernter, Kranzler, and col-
leagues, attention has shifted from DRD2 to ANKK1 and
TTC12 as the genes in this region most strongly associ-
ated with substance dependence. They initially con-
ducted a family-based association study37 of tobacco de-
pendence in a largely polysubstance-dependent sample
drawn fromsets of EuropeanAmerican andAfricanAmeri-
can affected (cocaine or opioid dependent) sibling pairs.
The strongest association in pooled African American and
EuropeanAmericandata includedANKK1 andTTC12SNPs
in amoderate tohighLDblock that overlaps ourmain find-
ings (eg, their top hits included rs4938012 [P = 8 106]
and rs4938013 [P = 3 105]). Of note, DSM-IV nico-
tine dependence is more highly correlated with other
DSM-IV substance dependence diagnoses than is Fager-
stro¨m score (for which they found much weaker associa-
tion). Further analyses implicated a 4-SNPhaplotype span-
ning TTC12 and ANKK1. They later focused39 on alcohol
dependence in 2EuropeanAmerican samples, finding only
nominally significant associations for individual SNPs; hap-
lotype-based analyses observed significant associations cen-
tering on TTC12,NCAM1, and ANKK1. A subsequent ex-
amination41 found that risk associated with most of these
haplotypes was for comorbid alcohol and illicit drug de-
pendence rather than alcohol dependence alone. In Col-
laborativeStudyon theGeneticsofAlcoholismfamilydata,38
nominal associations for alcohol-related phenotypes were
found in an overlapping ANKK1 region (including both
rs877138 and rs4938012). A Collaborative Study on the
Genetics of Alcoholism genome-wide association study44
found that rs10502172, amore upstreamTTC12 SNP,was
nominally associated with alcohol dependence
(P = 7.0 104). A Finnish population-based birth co-
hort study45 reported strong association of SNPs within a
haplotype block stretching from TTC12 toDRD2 (includ-
ing rs877138; P = .001) with smoking at age 14 years;
rs10502172 (P = 9.1 106) was most highly associated.
These SNPsweremoreweakly associatedwith smoking at
age31years.Overall, our associationsignal extensivelyover-
laps those of reports focusing on nicotine- and alcohol-
related phenotypes37,38,45; the weaker, independent asso-
ciationwith theNCAM1 SNP rs4492854 is consistentwith
prior reports.39,41 Our investigation provides strong evi-
dence of associationof individualANKK1 andTTC12 SNPs
with heroin and other illicit drug dependence, replicating
findings in a prior report.41 Despite these converging find-
ings, considerable variation in the intensity and location
of association was found across reports.37-39,41-45 Differ-
ences in examinedphenotype likely contributed to this vari-
ance because alcohol- and nicotine-related outcomes dif-
fer but are significantly correlated.
The protein encoded by ANKK1, a member of the re-
ceptor interacting protein serine/threonine kinases, is be-
lieved to play a role in signal transduction that includes ac-
tivationof transcription factors in response toenvironmental
factors.53ANKK1 is reportedly expressed in radial glia dur-
ing development and in astrocyteswithin the adult brain.54
ANKK1 expression is upregulatedby administrationof apo-
morphine, a dopamine agonist, and is temporally associ-
ated withDRD2 expression in developing mice.53-55 These
findings, coupled with the genes’ proximity, have led in-
vestigators toposit that theprotein encodedbyANKK1may
play an important role in the alterations in dopaminergic
signaling following drug exposure central to the addic-
tion process.53 TTC12, also expressed in the brain, con-
tains a tetratricopeptide repeat structure known to facili-
tate protein-proteinbinding and forwhich effects on steroid
hormone receptors have been reported.56 Further investi-
gation will be necessary to characterize more clearly the
roles these genes may play in the pathophysiology of il-
licit drug dependence.
Several limitations must be considered when inter-
preting our findings. Because our cases were ascer-
tained entirely fromNew SouthWales ORT clinics, gen-
eralizability to samples of individuals not currently in
treatment or from other areas will need to be demon-
strated. Our primary findings emerged after dividing
neighborhood controls into subsamples based on his-
tory of lifetime drug dependence; thus, replication in other
similarly ascertained samples would provide important
confirmation. It is possible that population stratifica-
tion could have contributed to our findings. Cases and
control groups primarily included individuals of Euro-
pean ancestry. Although we did observe ethnicity differ-
ences, the most substantial were between cases and ATR
controls. We conducted PCA prior to each comparison
Table 4. Comparison of 1459 Cases With 340 Neighborhood Controls Not Dependent on Illicit Drugs
Group
Risk Level, No. (%)a
0 1 2 3
Nondependent neighborhood controlsb 47 (32.4) 168 (21.8) 107 (15.2) 18 (10.1)
Heroin-dependent casesb 98 (67.6) 603 (78.2) 598 (84.8) 160 (89.9)
OR (95% CI) 1 [Reference] 1.69 (1.15-2.49) 2.62 (1.75-3.93) 4.30 (2.36-7.84)
Abbreviation: OR, odds ratio.
aRisk level indicates the number of rs877138 minor alleles plus the presence of an rs4492854 major allele. Mantel-Haenszel test: 21 = 35.40; P = 2.7 × 109
(linear trend).
bNumber of individuals are shown with column percentage in parentheses.
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and, when appropriate, included PCs to control for popu-
lation stratification. Post hoc comparisons of cases with
nondependent neighborhood controls that included 4PCs
as covariates produced similar results. Another corre-
lated phenotype (eg, a component of temperament) could
be responsible for the current association findings and
those previously reported. While this possibility is dif-
ficult to exclude, examinations that have incorporated
aspects of temperament have produced mixed re-
sults.40,47 Despite the considerably larger size of our sample
(3-fold larger than most prior association studies of
heroin dependence), it is possible that wemay have failed
to detect significant associations because of limited power
(ie, type II error). Similarly, the smaller size of the neigh-
borhood control subsamples either could be limiting sig-
nificant differences found in comparisons with cases or
between subgroups or could be resulting in spurious as-
sociations (ie, type I error). Finally, the reductions in
sample size produced by the more stringent exclusion
criteria (ie, including alcohol or tobacco dependence along
with illicit drug dependence) used for the neighbor-
hood control subgroups may have contributed to the
weaker observed associations by decreasing power.
In summary, we provide evidence that ANKK1 and
TTC12 SNPs are strongly associated with substance de-
pendence, substantially overlapping findings from other
reports.37-46 Our focus on illicit drug dependence is an
important extension of scope beyond that of prior stud-
ies. Additional investigations (eg, deep sequencing) can
characterize more definitively the polymorphisms most
highly associated with heroin and other illicit drug de-
pendence and determine the gene responsible for the ob-
served association. Finally, our findings highlight the im-
portance of considering substance exposure historywhen
selecting the most appropriate control group for genetic
investigations of substance dependence and raise an in-
triguing possibility that nondependent, highly substance-
exposed controls might prove particularly informative.
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